Bushu Pharmaceuticals has been commissioned by numerous customers to manufacture clinical trial materials and pharmaceuticals since the beginning of our business as a company specializing in contract manufacturing of pharmaceutical products. Through our numerous contract manufacturing projects, we have accumulated a wide range of business experiences, such as improving manufacturing technology and quality assurance levels, meeting strict delivery deadlines, and improving costs. With our partners from around the globe, we have grown to what we are today.

We have passed GMP inspections by the US FDA, EMA, and PMDA, and are exporting our products to 56 countries. Recently, we have launched the “GATEWAY to ASIA^®” project, which entails import of bulk products from internationally renowned biopharmaceutical companies and conduction of quality tests, quality inspections, secondary packaging, and supply of the products to Asian countries. Thus, we have focused our efforts on the support of global pharmaceutical companies that aim to expand their business to the Japanese and other Asian markets.

In September 2022, we acquired the Aizu Factory from Sanwa Kagaku Kenkyusho for the purpose of strengthening the basis of our solid dosage formulation business, and in 2023 we opened the Soka Packaging Center as our fifth base of manufacturing operations to reinforce our contract manufacturing capacity and capabilities in the face of a sustained increase in demand for biopharmaceutical products.

In addition, we will also strive to create and maintain a sustainable business environment while keeping our eyes on social issues like CSR and SDGs and valuing concept of BCP and EHS.

In order to realize our corporate philosophy (mission) "Supporting the global healthcare industry to create a healthier tomorrow," we will make further efforts by refining our quality, fulfill stable supply, flexibility, speed, cost, technical capabilities, and human resource development.

We would like to thank you again for your continued support.